Shmuel Burg is a Ph.D. student at the Engineering Faculty of Bar-Ilan University, Israel. In 2004, he received his B.Sc. degree in Physics from Bar-Ilan University. From 2004-2010, Shmuel served as an academic officer in the Israeli Navy and was expertized in underwater acoustics. In 2012, he received his M.Sc. degree in Physics from Bar-Ilan University. In the framework of his M.Sc thesis on ferromagnetic spintronics, he published a paper in Physica Status Solidi B.
In 2019, in the framework of his Ph.D. studies, he published a paper in Applied Physics Letters on magnetically aggregated fluorescent biosensors (MAB) to detect and identify biomarker targets at very low concentrations. In 2022, he published the second paper in the framework of his Ph.D. studies in Talanta Open on high throughput optical modulation biosensing for highly sensitive and rapid detection of biomarkers.
During the COVID-19 pandemic, the Israeli Ministry of Health and the Israeli Ministry of Defense signed a contract with the company to manufacture a fully automated ht-OMB system (which was later termed the OMBi Detection system). Due to his extensive knowledge in the field, Shmuel worked with MagBiosense engineers to successfully develop the system. Using the OMBi system, 306 SARS-CoV-2 RNA extracts were tested in an OMBi-based molecular assay. The assay successfully detected 67 out of 70 SARS-CoV-2-positive samples (95% sensitivity). In addition, the assay successfully identified all 236 SARS-CoV-2-negative samples as negative (100% specificity). In addition, the OMBi shortened the overall turnaround assay time – 37 minutes in comparison to 90 minutes of the RT-qPCR assay.
Shmuel's current research is focused on developing a microfluidic system suitable for point-of-care (POC) applications. The goal is to develop a small footprint and cost-effective OMB-based system that can incorporate a disposable cartridge and be placed at the doctor’s office or other non-lab settings.
In 2019, in the framework of his Ph.D. studies, he published a paper in Applied Physics Letters on magnetically aggregated fluorescent biosensors (MAB) to detect and identify biomarker targets at very low concentrations. In 2022, he published the second paper in the framework of his Ph.D. studies in Talanta Open on high throughput optical modulation biosensing for highly sensitive and rapid detection of biomarkers.
During the COVID-19 pandemic, the Israeli Ministry of Health and the Israeli Ministry of Defense signed a contract with the company to manufacture a fully automated ht-OMB system (which was later termed the OMBi Detection system). Due to his extensive knowledge in the field, Shmuel worked with MagBiosense engineers to successfully develop the system. Using the OMBi system, 306 SARS-CoV-2 RNA extracts were tested in an OMBi-based molecular assay. The assay successfully detected 67 out of 70 SARS-CoV-2-positive samples (95% sensitivity). In addition, the assay successfully identified all 236 SARS-CoV-2-negative samples as negative (100% specificity). In addition, the OMBi shortened the overall turnaround assay time – 37 minutes in comparison to 90 minutes of the RT-qPCR assay.
Shmuel's current research is focused on developing a microfluidic system suitable for point-of-care (POC) applications. The goal is to develop a small footprint and cost-effective OMB-based system that can incorporate a disposable cartridge and be placed at the doctor’s office or other non-lab settings.
View contact details
